Viral Vector Manufacturing: Market Size & Forecast 2026

The global viral vector manufacturing market stands at approximately USD 7.8 billion in 2025 (base year), growing at a 17.5% CAGR through 2032 to reach roughly USD 23.4 billion. The market sits in a structurally tight configuration: AAV serotypes account for 42% of manufacturing revenue and are the hardest vector type to produce at scale; the top four CDMOs hold an estimated 35-45% share; and plasmid DNA, the primary upstream feedstock, trades at roughly USD 1.85 million per metric ton for research-grade material, making it the single largest variable input cost. The demand surge is real, gene therapy clinical trials alone account for 48% of vector demand, and eight AAV-based therapies have received regulatory approval in major markets since 2022. What constrains buyers is the CapEx wall: commercial-scale AAV manufacturing runs a 60-70% capital intensity profile, and qualified production

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.